Goldman Sachs Upgrades Taysha Gene Therapies on Rett Syndrome Potential
Goldman Sachs upgrades Taysha Gene Therapies to Buy with an $11 target, citing strong confidence in the company’s Rett syndrome program and REVEAL study expectations.
/ 3 items
#TSHA↓
Gene Therapy Showdown: Taysha's Speed vs. Neurogene's Durability
A look at why analysts are favoring Neurogene over Taysha in the race for gene therapy approvals, focusing on study design, FDA alignment, and long-term patient outcomes.
Major Step Forward for Taysha's TSHA-102 Gene Therapy in Rett Syndrome
The FDA has granted Breakthrough Therapy designation to TSHA-102 for Rett Syndrome, acknowledging its potential to redefine treatment.